Developer docs
API playgroundTry for free, no card

Search company profiles

VintaBio

Full company profile

uuid0000faq

Namestring
VintaBio
Legal namestring
VintaBio LLC
Websiteurl
vintabio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

VintaBio is a Philadelphia-based contract development and manufacturing organization (CDMO) founded in 2020 that provides viral vector manufacturing services for cell and gene therapy developers. The company emerged from stealth in April 2023 with $64 million in funding led by Decheng Capital and operates a 22,434 sq ft purpose-built facility at the Philadelphia Navy Yard featuring BSL2-ISO7/ISO8 classified cleanrooms and 5 dedicated cGMP suites for cell expansion, solution prep, processing, and fill/finish, plus dedicated process development, toxicology (GLP), and RUO vector core areas.

The company's core offering is VintaProcess™, a proprietary Intensified Adherent Technology platform that keeps HEK293 cells in their natural adherent state within small-footprint bioreactors, contrasting with conventional suspension-based viral vector production. The platform comprises six integrated components — VintaCell (cGMP cell line), VintaSeed (surface area amplification), VintaFect (transfection reagent), VintaSep (purification system), and VintaDP (final formulations) — and is claimed to deliver 43% lower process time, 30% lower raw material costs, 5x higher high-purity vector output, and 90% full capsids. Services span process development (platform bridging, scale-up, process characterization, QbD/CMC support), cGMP manufacturing (AAV and LVV production, fill/finish), and analytical development for clinical and commercial programs.

VintaBio operates a fee-for-service CDMO business model targeting biotech and pharmaceutical companies developing cell and gene therapies, with a horizontal go-to-market focused exclusively on viral vector manufacturing for the CGT developer segment. The company sells through direct B2B enterprise engagement with biotech and pharma leadership, leveraging the team's pedigree — including co-developers of FDA-approved Luxturna and Zolgensma from Spark Therapeutics — to win contracts. Pricing is quote-based and not publicly disclosed, with revenue generated through project-based contracts. Customer logos are not disclosed in available sources.

Short descriptiontext

VintaBio is a Philadelphia-based CDMO providing viral vector (AAV and lentiviral) manufacturing services to cell and gene therapy developers, using its proprietary VintaProcess™ Intensified Adherent Technology platform from a 22,434 sq ft cGMP facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, cell and gene therapy, contract development manufacturing, biopharmaceutical CDMO services, AAV lentiviral production
Industry3 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceutical CDMO — Viral Vector Manufacturing Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

VintaBio operates as a contract development and manufacturing organization (CDMO), providing fee-for-service viral vector manufacturing to biotech and pharmaceutical clients. Services span from process development through cGMP manufacturing and analytical testing, with revenue generated through project-based contracts for clinical and commercial supply.

vintabio.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1VintaProcess™
Description

Advanced Intensified Adherent Technology platform that generates high-yield, high-purity viral vectors for clinical and commercial cell and gene therapies using a small footprint single-stream process.

vintabio.com
+5 more records
Core offering1 text field

VintaBio is a contract development and manufacturing organization (CDMO) that produces viral vectors—primarily AAV and lentiviral vectors—for biotech and pharmaceutical companies developing cell and gene therapies. The company delivers end-to-end manufacturing services spanning process development, cGMP manufacturing, and analytical testing using its proprietary VintaProcess™ Intensified Adherent Technology platform, operated from a 22,434 sq ft BSL2-ISO7/ISO8 manufacturing facility in Philadelphia, Pennsylvania.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 43% reduction in process time
+5 more records
Product overview1 text field

VintaBio is a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies. The company's core offering is the proprietary VintaProcess™ platform, which includes five integrated components (VintaCell, VintaSeed, VintaFect, VintaSep, and VintaDP) that work together to enable high-yield, high-purity viral vector production. This platform is supported by end-to-end services including Process Development, cGMP Manufacturing, and Analytical Development, all delivered from the company's state-of-the-art 22,434 sq ft facility in Philadelphia featuring BSL2 containment and ISO7/ISO8 classified cleanrooms with 5 dedicated cGMP suites.

Product and service3 records
1Process Development Services
CategoryCDMO service — process development
Description

End-to-end solution for viral vector manufacturing spanning cell line through drug product, with platform bridging, pre-clinical and toxicology batches, scale up/out, process characterization, Quality by Design (QbD) and CMC support, analytical development, and formulation development for cell and gene therapy developers.

2cGMP Manufacturing Services
CategoryCDMO service — cGMP manufacturing
Description

cGMP viral vector manufacturing for cell and gene therapy programs, including cGMP cell line development, AAV and lentiviral vector (LVV) production, process validation, CMC support, cGMP analytical testing, stability strategy support, assay qualification and validation, and formulation/fill-finish operations.

3Analytical Development Services
CategoryCDMO service — analytical development
Description

Analytical services for viral vector product release including assay development, assay qualification and validation, in-process sample testing, lot release testing, and stability support for cell and gene therapy developers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large, established CDMO with a dedicated gene therapy viral vector business (formerly Paragon BioServices). Directly comparable as a viral vector CDMO serving AAV/lentiviral programs for cell and gene therapy developers, but at much larger scale and with broader service portfolio.

TypeBroad incumbent
Description

Global biopharma CDMO with significant viral vector and cell therapy manufacturing capacity. Comparable as a viral vector CDMO for gene therapy developers, but operates globally with much larger installed capacity and broader modality coverage.

TypeDirect peer
Description

King of Prussia, PA-based CGT CDMO offering viral vector, cell therapy, and plasmid manufacturing. Directly comparable as a viral vector CDMO for AAV/lentiviral programs; VintaBio's VP Technology Lucia Fernandez previously headed viral vector tech transfer there.

4National Resilience
TypeDirect peer
Description

U.S.-focused biotech manufacturer with end-to-end capabilities across biologics, viral vectors, and cell therapies. Directly comparable as a viral vector CDMO for gene therapy developers, with broader modality coverage but similar domestic, end-to-end positioning.

TypeDirect peer
Description

Columbus, Ohio-based CDMO specializing in AAV and other viral vectors for gene therapy, spun out of Nationwide Children's Hospital. Directly comparable as a viral vector CDMO with cGMP manufacturing, process development, and analytical services for clinical and commercial gene therapy programs.

TypeDirect peer
Description

Columbus, Ohio-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Directly comparable as a viral vector CDMO with end-to-end process development, cGMP manufacturing, and fill/finish for AAV-based gene therapy programs.

TypeDirect peer
Description

Indianapolis-based viral vector CDMO specializing in AAV and lentiviral manufacturing for gene therapy developers. Directly comparable as a viral vector CDMO offering process development, cGMP manufacturing, and analytical services to early-stage and clinical-stage gene therapy clients.

TypeBroad incumbent
Description

Global CDMO with cell and gene therapy viral vector capabilities alongside biologics services. Comparable as a viral vector CDMO, but with broader portfolio including mammalian and microbial biologics manufacturing.

TypeBroad incumbent
Description

Global life sciences company with viral vector manufacturing services for cell and gene therapy. Comparable as a viral vector CDMO, but operating as part of a much larger life sciences portfolio including tools, services, and pharma services.

TypeRegional player
Description

European-based CDMO with viral vector manufacturing expertise for gene therapy applications. Comparable as a viral vector CDMO with similar modality focus, but operates primarily in EU geography rather than U.S.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VintaBio

Biopharmaceutical CDMO — Viral Vector Manufacturing Servicesvintabio.com

VintaBio is a Philadelphia-based CDMO providing viral vector (AAV and lentiviral) manufacturing services to cell and gene therapy developers, using its proprietary VintaProcess™ Intensified Adherent Technology platform from a 22,434 sq ft cGMP facility.

What VintaBio does

VintaBio is a Philadelphia-based contract development and manufacturing organization (CDMO) founded in 2020 that provides viral vector manufacturing services for cell and gene therapy developers. The company emerged from stealth in April 2023 with $64 million in funding led by Decheng Capital and operates a 22,434 sq ft purpose-built facility at the Philadelphia Navy Yard featuring BSL2-ISO7/ISO8 classified cleanrooms and 5 dedicated cGMP suites for cell expansion, solution prep, processing, and fill/finish, plus dedicated process development, toxicology (GLP), and RUO vector core areas.

The company's core offering is VintaProcess™, a proprietary Intensified Adherent Technology platform that keeps HEK293 cells in their natural adherent state within small-footprint bioreactors, contrasting with conventional suspension-based viral vector production. The platform comprises six integrated components — VintaCell (cGMP cell line), VintaSeed (surface area amplification), VintaFect (transfection reagent), VintaSep (purification system), and VintaDP (final formulations) — and is claimed to deliver 43% lower process time, 30% lower raw material costs, 5x higher high-purity vector output, and 90% full capsids. Services span process development (platform bridging, scale-up, process characterization, QbD/CMC support), cGMP manufacturing (AAV and LVV production, fill/finish), and analytical development for clinical and commercial programs.

VintaBio operates a fee-for-service CDMO business model targeting biotech and pharmaceutical companies developing cell and gene therapies, with a horizontal go-to-market focused exclusively on viral vector manufacturing for the CGT developer segment. The company sells through direct B2B enterprise engagement with biotech and pharma leadership, leveraging the team's pedigree — including co-developers of FDA-approved Luxturna and Zolgensma from Spark Therapeutics — to win contracts. Pricing is quote-based and not publicly disclosed, with revenue generated through project-based contracts. Customer logos are not disclosed in available sources.

VintaBio firmographics

Firmographics
Name
VintaBio
Legal name
VintaBio LLC
Website
https://vintabio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
VintaBio is a Philadelphia-based CDMO providing viral vector (AAV and lentiviral) manufacturing services to cell and gene therapy developers, using its proprietary VintaProcess™ Intensified Adherent Technology platform from a 22,434 sq ft cGMP facility.
Ownership category
akta.pro rank

VintaBio industry classification

Industry
Product category
Biopharmaceutical CDMO — Viral Vector Manufacturing Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vector manufacturing
  • Cell and gene therapy
  • Contract development manufacturing
  • Biopharmaceutical CDMO services
  • AAV lentiviral production

Where VintaBio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

VintaBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: VintaBio operates as a contract development and manufacturing organization (CDMO), providing fee-for-service viral vector manufacturing to biotech and pharmaceutical clients. Services span from process development through cGMP manufacturing and analytical testing, with revenue generated through project-based contracts for clinical and commercial supply.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

VintaBio product offering

Product offering

Core offering

VintaBio is a contract development and manufacturing organization (CDMO) that produces viral vectors—primarily AAV and lentiviral vectors—for biotech and pharmaceutical companies developing cell and gene therapies. The company delivers end-to-end manufacturing services spanning process development, cGMP manufacturing, and analytical testing using its proprietary VintaProcess™ Intensified Adherent Technology platform, operated from a 22,434 sq ft BSL2-ISO7/ISO8 manufacturing facility in Philadelphia, Pennsylvania.

Product overview

VintaBio is a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies. The company's core offering is the proprietary VintaProcess™ platform, which includes five integrated components (VintaCell, VintaSeed, VintaFect, VintaSep, and VintaDP) that work together to enable high-yield, high-purity viral vector production. This platform is supported by end-to-end services including Process Development, cGMP Manufacturing, and Analytical Development, all delivered from the company's state-of-the-art 22,434 sq ft facility in Philadelphia featuring BSL2 containment and ISO7/ISO8 classified cleanrooms with 5 dedicated cGMP suites.

Differentiator

Problem solved

Functional benefit

Brands

  • VintaProcess™: Advanced Intensified Adherent Technology platform that generates high-yield, high-purity viral vectors for clinical and commercial cell and gene therapies using a small footprint single-stream process.
  • VintaCell
  • VintaSeed
  • VintaFect
  • VintaSep
  • VintaDP

Products and services

  • Process Development Services End-to-end solution for viral vector manufacturing spanning cell line through drug product, with platform bridging, pre-clinical and toxicology batches, scale up/out, process characterization, Quality by Design (QbD) and CMC support, analytical development, and formulation development for cell and gene therapy developers.
  • cGMP Manufacturing Services cGMP viral vector manufacturing for cell and gene therapy programs, including cGMP cell line development, AAV and lentiviral vector (LVV) production, process validation, CMC support, cGMP analytical testing, stability strategy support, assay qualification and validation, and formulation/fill-finish operations.
  • Analytical Development Services Analytical services for viral vector product release including assay development, assay qualification and validation, in-process sample testing, lot release testing, and stability support for cell and gene therapy developers.

Quantifiable outcome

  • 43% reduction in process time
  • +5 more outcomes

Companies that use VintaBio

Customer profile

Segments1 record

Ideal customer profiles1 record

VintaBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

VintaBio partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

VintaBio competitors and assessment

Company assessment

Broad incumbents

  • Catalent (Paragon Gene Therapy): Large, established CDMO with a dedicated gene therapy viral vector business (formerly Paragon BioServices). Directly comparable as a viral vector CDMO serving AAV/lentiviral programs for cell and gene therapy developers, but at much larger scale and with broader service portfolio.
  • Lonza Cell & Gene: Global biopharma CDMO with significant viral vector and cell therapy manufacturing capacity. Comparable as a viral vector CDMO for gene therapy developers, but operates globally with much larger installed capacity and broader modality coverage.
  • AGC Biologics: Global CDMO with cell and gene therapy viral vector capabilities alongside biologics services. Comparable as a viral vector CDMO, but with broader portfolio including mammalian and microbial biologics manufacturing.
  • Thermo Fisher Scientific Viral Vector Services: Global life sciences company with viral vector manufacturing services for cell and gene therapy. Comparable as a viral vector CDMO, but operating as part of a much larger life sciences portfolio including tools, services, and pharma services.

Direct peers

  • Center for Breakthrough Medicines: King of Prussia, PA-based CGT CDMO offering viral vector, cell therapy, and plasmid manufacturing. Directly comparable as a viral vector CDMO for AAV/lentiviral programs; VintaBio's VP Technology Lucia Fernandez previously headed viral vector tech transfer there.
  • National Resilience: U.S.-focused biotech manufacturer with end-to-end capabilities across biologics, viral vectors, and cell therapies. Directly comparable as a viral vector CDMO for gene therapy developers, with broader modality coverage but similar domestic, end-to-end positioning.
  • Andelyn Biosciences: Columbus, Ohio-based CDMO specializing in AAV and other viral vectors for gene therapy, spun out of Nationwide Children's Hospital. Directly comparable as a viral vector CDMO with cGMP manufacturing, process development, and analytical services for clinical and commercial gene therapy programs.
  • Forge Biologics: Columbus, Ohio-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Directly comparable as a viral vector CDMO with end-to-end process development, cGMP manufacturing, and fill/finish for AAV-based gene therapy programs.
  • Genezen: Indianapolis-based viral vector CDMO specializing in AAV and lentiviral manufacturing for gene therapy developers. Directly comparable as a viral vector CDMO offering process development, cGMP manufacturing, and analytical services to early-stage and clinical-stage gene therapy clients.

Regional players

  • Skyepharma (Vectalys / PeptiMimesis): European-based CDMO with viral vector manufacturing expertise for gene therapy applications. Comparable as a viral vector CDMO with similar modality focus, but operates primarily in EU geography rather than U.S.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VintaBio social profiles

Digital presence

VintaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VintaBio leadership team

Management profile

Number of profiles

Profiles5 records

VintaBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VintaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VintaBio

What does VintaBio do?

VintaBio is a contract development and manufacturing organization (CDMO) that produces viral vectors—primarily AAV and lentiviral vectors—for biotech and pharmaceutical companies developing cell and gene therapies. The company delivers end-to-end manufacturing services spanning process development, cGMP manufacturing, and analytical testing using its proprietary VintaProcess™ Intensified Adherent Technology platform, operated from a 22,434 sq ft BSL2-ISO7/ISO8 manufacturing facility in Philadelphia, Pennsylvania.

Is VintaBio a public or private company?

VintaBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was VintaBio founded?

VintaBio was founded in 2023. It employs 11 to 50 people.

Where is VintaBio based?

VintaBio is headquartered in Philadelphia, United States, in the North America region.

How does VintaBio make money?

One revenue line is on record: contract Manufacturing Services.

Who are VintaBio's main competitors?

Broad incumbents on record are Catalent (Paragon Gene Therapy), Lonza Cell & Gene, AGC Biologics and Thermo Fisher Scientific Viral Vector Services. Direct peers are Center for Breakthrough Medicines, National Resilience, Andelyn Biosciences, Forge Biologics and Genezen. Skyepharma (Vectalys / PeptiMimesis) is listed as a regional player.

Does VintaBio have an API?

No public API is recorded for VintaBio.

What industry is VintaBio in?

VintaBio's product category is Biopharmaceutical CDMO — Viral Vector Manufacturing Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FiercePharmaVintaBio assets go on auction block as CGT viral vector demand slowsVintaBio's manufacturing facility and intellectual property are being sold via a state legal process, with bidding due Dec. 15. The 22,500-square-foot Philadelphia plant, a $17 million investment, is up for sale amid slowing viral vector demand, as capacity outpaces clinical need.PR NewswireVintaBio Names Jennifer Kingsley Chief Commercial OfficerVintaBio, a cell and gene therapy contract development and manufacturing organization (CDMO), has appointed Jennifer Kingsley as its first Chief Commercial Officer to lead the company's commercial strategy. Kingsley brings 25 years of life science commercial experience, having spent the past decade at Cytiva, where she most recently served as Commercial Zone Leader. VintaBio has also hired Ann Lee as Chief of Staff and has raised $64 million in venture funding to develop a new 22,500 square foot manufacturing facility in Philadelphia.PR NewswireVintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene TherapiesVintaBio emerged from stealth with $64 million in funding led by Decheng Capital and a new CEO, David Radspinner. The company's 22,500-square-foot Philadelphia facility is open and accepting orders for viral vector manufacturing. The funding supports scaling cell and gene therapies.BioSpaceVintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene TherapiesVintaBio has emerged from stealth mode with $64 million in funding led by Decheng Capital and a new CEO, David Radspinner, to support its custom-built viral vector manufacturing facility in Philadelphia. The company aims to alleviate supply bottlenecks in cell and gene therapy development by leveraging the founders' experience with the first FDA-approved therapies. This expansion provides specialized CDMO services designed to scale advanced medicine production for patients.American City Business JournalsVintaBio, located in Philadelphia Navy Yard, raises $64M in fundingVintaBio, a cell and gene therapy contract manufacturer based in Philadelphia, has emerged from stealth mode with $64 million in funding. The company is utilizing this capital to support its custom-built facility at the Navy Yard and the leadership of a new veteran healthcare executive as CEO.Endpoints NewsEx­clu­sive: Cell and gene ther­a­py CD­MO VintaBio emerges on­to the scene with $64M and a new CEOA contract manufacturer named VintaBio is emerging from stealth with $64 million in funding and a new CEO. The company is entering the cell and gene therapy industry, which is experiencing significant activity. VintaBio's emergence coincides with an increased focus on advancements in the field of cell and gene therapies.Venture Capital Access OnlineVintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene TherapiesVintaBio has secured $64 million in funding to enhance its capabilities in developing viral vectors for cell and gene therapy, and has opened a specialized manufacturing facility in Philadelphia. The company aims to alleviate the bottleneck in viral vector supply to support the growing demand in the industry. With a leadership team experienced in pioneering gene therapies, VintaBio is positioned to advance treatment access for patients in need.Ow.ly Link ShortenerCell Therapy Pioneers Team Up to Found Viral Vector CDMO Backed by $64MVintaBio announced a $64 million financing round led by Decheng Capital to support its new Philadelphia manufacturing facility for viral vectors used in cell and gene therapies. The company, co-founded by University of Pennsylvania researchers involved in the development of Kymriah, aims to address sector-wide supply constraints by providing manufacturing services to pharmaceutical companies, academic institutions, and government bodies.VC News DailyVintaBio Emerges With $64MVintaBio, a life sciences company specializing in viral vectors for cell and gene therapy development, emerged from stealth with $64 million in funding led by Decheng Capital. The company was founded by Junwei Sun and Dr. Shangzhen Zhou, who previously developed the first viral vectors used for FDA-approved gene therapies and has a custom-built manufacturing facility in Philadelphia that is now open and accepting orders. The company's team brings over a century of combined experience in cell and gene therapy development and aims to address the current bottleneck in viral vector manufacturing.